ESPERION CORPORATE OVERVIEW

November 2020

ESPERION The Lipid Management Company

SAFE HARBOR

FORWARD- LOOKING STATEMENTS

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the clinical development and commercialization plans for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, including ESPERION's timing, designs, plans for announcement of results regarding its CLEAR Outcomes study and other ongoing clinical studies for bempedoic acid tablet and the bempedoic acid / ezetimibe combination fixed dose tablet, timing for the review and approval of expanded indications for their effect on cardiovascular events, ESPERION's expectations for the market for medicines to lower LDL-C, including the commercial launch and market adoption of bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet in the United States and European Union, and ESPERION's financial outlook, including expectations for future revenues from its product sales, partnership collaborations and other sources. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause ESPERION's actual results to differ significantly from those projected, including, without limitation, delays or failures in ESPERION's clinical development and commercialization plans, or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, that Otsuka and DSE are able to successfully commercialize its products, the impact of COVID-19 on our business, clinical activities and commercial development plans, and the risks detailed in ESPERION's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and ESPERION disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

ESPERION | Helping patients meet goals

Everybody knows someone struggling with their cholesterol …

We believe changing the world requires focus: to discover, develop, and commercialize oral, once daily, non-statin medicines for battling bad cholesterol. And people should be able to afford and access their medicines…

ESPERION has a proven 20 year-history of delivering innovation toward this singular mission and we are the only publicly held company with a singular focus on fighting bad cholesterol.

ESPERION LEADERSHIP TEAM
ALL WITH STRONG CONNECTIONS TO OUR PURPOSE

Tim Mayleben, President and Chief Executive Officer
Tim's father passed away at 48 from a heart attack and his wife currently takes NEXLETOL after years of statin intolerance and battling uncontrolled familial high cholesterol

Rick Bartram, Chief Financial Officer
Rick's father had CVD and T2D,and high cholesterol uncontrolled by statins alone, which resulted in several MIs and stroke prior to his death at age 58

Mark Glickman, Chief Commercial Officer
Motivated by family experience, today, his drive is being able to help the millions of patients struggling to achieve cv health goals

Ashley Hall, Chief Development Officer
Despite being a lifelong professional and all around athlete, Ashley's father had his first heart attack when he was in his 50's and a second one in his 70's due to uncontrolled familial high cholesterol

Ken Fiorelli, Chief Technical Operations Officer
Several of Ken's family members have struggled with high cholesterol and T2D. Treatment with statins did not bring their cholesterol levels to target

~97 Million People in the United States Have High Levels of Bad Cholesterol



Did you know?

- 8.7 Million Patients in the U.S. Are Taking Statins, but Need Additional Therapy to Reach Their LDL-C Goals
- 9.6 Million Patients in the U.S. with High LDL-C Are Not on Statins, often due to Tolerability Concerns

18 Million Need Additional LDL-C Lowering

~44 Million Diagnosed; 34 Million on a Statin

Source: ZS Associates primary and secondary research, Sep-Oct 2018. Primary research N = 350 healthcare practitioners

#1 cause of death globally is cardiovascular disease

- Significantly less innovation versus other therapy areas [1]
- Causes More Annual Deaths Than All Forms of Cancers Combined[2]
- Accounts for ~1 in 3 Deaths in the U.S. and Europe[2]

CDC estimates heart disease deaths will increase 25% by 2030

[1] Mckinsey & Co.
[2] World Health Organization
[3] CDC 2017-2030

Elevated cholesterol is an established risk factor for cardiovascular (CV) disease

We compete Against pain points

Most innovation in our therapy area is delivered by injection

Which one would You choose?

4 out of 5 patients prefer a pill*

Patients have been waiting for years for oral, once daily non-statin medicines

* *https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003606/*

ESPERION®

WHAT DO PATIENTS WANT AND NEED IN NEW LDL-C LOWERING MEDICINES? *FAMILIARITY*

Positive Impact

Reduce their already high bad cholesterol in a significant way in a form they know

Convenience

Daily pills that are easy to take and refill, completely avoiding clinics and pharmacies if desired

Safe and Tolerable

With less muscle pain

Works well with other medications

Many patients have multiple treatment needs due to diabetes or inflammation

ESPERION FILLS THE GAP IN TREATMENT OPTIONS

Total Bad Cholesterol Lowering Paradigm

STATINS
Mostly Generic, Widely Used

EZETIMIBE

ORAL NON-STATIN GAP

Higher Cost SHOTS (PCSK9i)

Total LDL-C Non-Statin Market (Adjunct)

WE SEEK TO FILL GLOBAL UNMET NEEDS

We are evolving into a Leading Global, Research Driven, Commercially Thriving Virtual Company

2018

- No Approved Products
- No Commercial Team
- 2 clinical programs in progress
- No Alliances

2023 Aspirations

- Several Approved Products with multiple indications
- Multiple Programs and Indications in Development
- Multiple Development and Commercial Alliances with Leading Global Companies

Partnering for Global Commercial Success
Companies with Proven Cardiovascular Excellence

Daiichi Sankyo Europe
(Product branded as NILEMDO™ & NUSTENDI™)

Daiichi-Sankyo

European Collaboration Overview:
- Largest EU agreement in history
- $900M in milestones plus royalties
  - $300M received to date
  - 15-25% royalty on all net sales
  - $300M milestone linked to CLEAR CVOT results
- Marketing Authorization Transfer to DSE complete
- Launched both medicines in Nov. 2020
- 1,000+ Cardiology-focused commercial team

Otsuka Pharmaceutical Co.

Otsuka

Japan Collaboration Overview:
- Largest Japanese agreement in history
- +$600M in milestones and development costs plus royalties
  - $60M received to date
  - 15-30% royalty rate on all net sales
  - $50M milestone linked to CLEAR CVOT results
- Otsuka responsible for development, regulatory approvals, and commercialization in Japan

Rest of World Deal (Non EU, Japan) on track for Q4 2020

ESPERION

EXPANDING THE FRANCHISE

- **Fixed Combination Drug Products with bempedoic acid, enhancing to make more efficacious**
- **Potential In-licensed Programs**

A HISTORY OF DELIVERING ON OUR COMMITMENTS

ESPERION® The Lipid Management Company

THE FUTURE LOOKS BRIGHT



WE ARE JUST LEAVING THE RUNWAY

Differentiated Pricing, Positioning & Messaging

Broad, High Quality Managed Care Coverage

Health Care Provider Engagement & Education

OUR FIRST-IN-CLASS MEDICINES FDA-APPROVED IN FEBRUARY 2020

NEXLETOL®
(bempedoic acid) Tablets
are the first oral,
once-daily, non-statin LDL-C
lowering medicine approved
since 2002 for indicated
patients

Available in U.S.
Since March 2020

NEXLIZET®
(bempedoic acid and ezetimibe)
Tablets
are the first oral non-statin, LDL-C
lowering combination medicine
ever approved

Available in U.S. since July 2020

NEXLETOL® and NEXLIZET® are each indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.

Limitations of Use: The effect of NEXLETOL®and NEXLIZET® on cardiovascular morbidity and mortality has not been determined.

NEXLETOL® and NEXLIZET® available by prescription only.
Known as NILEMDO ™ (bempedoic acid) &
NUSTENDI ™ (bempedoic acid and ezetimibe) in Europe

Important Safety Information can be found on slides 33/34. Please see full prescribing information at:
https://pi.esperion.com/nexletol/nexletol-pi.pdf and https://pi.esperion.com/nexlizet/nexlizet-pi.pdf

BROAD AND HIGH-QUALITY PAYOR COVERAGE AHEAD OF EXPECTATIONS AND OTHER LAUNCHES

Payor Coverage Exceeding Expectations



Coverage is in Preferred Tiers with Lower Patient Costs



PROGRESS, DESPITE PANDEMIC

5,000+
Doctors writing at least one prescription

2,000+
patients taking our medicines every week

270,000+
Seven-day starter packs Physicians have requested and received to begin patients on our medicines easily

IMPACTS FROM COVID-19:

Doctors offices were not open for initial launch period

When open:

Some do not see industry reps

Doctors focused on acute patients first

NOTHING BEATS FACE-TO-FACE

Our team is committed to reaching HCPs on their terms, in their time in accordance with CDC protocols

At 70% in person visits, we are leading the way

Total biopharma details reached 85% vs. baseline of which remote details account for approximately 54% of all prescriber details

Specialty in-person details remain at approximately 48% of baseline with Oncology and Primary care at 22% and 42% respectively

Source: IQVIA



POSITIVE REACTIONS FROM HEALTH CARE PROVIDERS

"A lot of patients are interested in this when I present it to them because it is an oral formulation"
Cardiologist

"One nice thing about these medicines is that they are just one dose. It really clears up the confusion when prescribing"
Primary Care Physician

SCRIPTS (RPE) GREW OVER 500% FROM 2Q 2020

While New-to-Brand in overall LDC-C market was down ~30%

Quarterly Franchise RPE Trend



Franchise RPE Trend Since Launch

*Based on Symphony data

RPE = Retail Prescription Equivalence; derived by normalizing the extended units Rx (no. of tablets) to determine the 30-day supply equivalent

ESPERION

SIGNIFICANT OPPORTUNITY IN A UNIQUELY SIZED MARKET



Market Opportunity: Patients

- 44M hypercholesterolemia diagnosed patients in the US
- 8.7M are on statins but not at LDL-C goal
- 9.6M are currently not on statin therapy to address high LDL cholesterol[2]

Market Opportunity: Prescriptions

- 245 million LDL-C prescriptions written annually in the US by ~720,000 prescribers
- ~38,000 highest-volume prescribers make up 40% of the entire LDL-C market, or an average of 2,600 Rx per year



Sources: ZS Associates Market Sizing and Forecasting Project, September 2018. N=300 Physicians and Symphony Health METYS prescription audit

ESPERION



Data on File: ZS Associates Market Sizing and Forecasting Project, December 2019. N=350 Physicians

TO RAISE AWARENESS AND INSPIRE ACTION, WE'VE RECENTLY LAUNCHED OUR DIRECT-TO-CONSUMER CAMPAIGN



ESPERION

OUR MEDICINES BECAME AVAILABLE IN GERMANY IN NOVEMBER

Largest Market & EU Opportunity through our EU Partner, DSE

CLEAR OUTCOMES STUDY HAS POTENTIAL FOR PATIENTS AND COMPANY

First-of-its-kind cardiovascular outcomes trial, following more than 14,000 patients with documented statin intolerance

There are approximately 10 million statin intolerant patients in the US.

We've reached over 50% of primary MACE endpoints to date

Fully enrolled in August 2019 and on-track to read-out in 2H 2022

ESPERION

FINANCIAL OVERVIEW

ESPERION The Lipid Management Company

DIVERSIFIED REVENUE STREAMS ON TOP OF STRONG CASH POSITION

U.S. Net Product Sales increased

5 X

quarter over quarter
Q2 $0.6M
Q3 $3.3M

Ex-U.S. Collaboration Milestones

$213M YTD

1st Royalty Expected Q4 2020

Ex-U.S. Royalty Revenues

Cash Balance $216M at end of Q3

Multiple Funding Resources for Financial Flexibility

Strengthening the Balance Sheet Opportunistically

Key Financial Data	
FY Revenue	No Guidance Before 2022
FY 2020 R&D Guidance	$135 - $145
FY 2020 SG&A Guidance	$200 - $210 4Q20 inclusive of DTC campaign launch
FY 2020 Op Ex Guidance[1]	**$335 - $355M**
Common Shares Outstanding	Basic 27.9M; Fully Diluted 32.8M

*Excludes $30M of non-cash stock based compensation expense

ESPERION

Every Day, We Have More Reasons to Believe In What's Ahead

IMPORTANT SAFETY INFORMATION

ESPERION® The Lipid Management Company

NEXLETOL® SAFETY PROFILE

- Contraindications: None
- Warnings and Precautions:
  - Hyperuricemia: NEXLETOL may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day) due to increased risk of adverse events.
- Most common adverse reactions in ≥2% of patients taking NEXLETOL and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile – please see https://pi.esperion.com/nexletol/nexletol-pi.pdf

NEXLIZET® SAFETY PROFILE

- Contraindication: Known hypersensitivity to ezetimibe tablets
- Warnings and Precautions:
  - Hyperuricemia: Bempedoic acid may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout.
  - Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture.
- Avoid concomitant use with simvastatin (>20 mg/day) or pravastatin (>40 mg/day). Monitor cyclosporine concentrations with cyclosporine. If cholelithiasis is suspected in a patient receiving fenofibrate, consider alternative lipid-lowering therapy.
- Most common adverse reactions in >2% of patients taking NEXLIZET and more frequently than placebo:
  - Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes, diarrhea, fatigue, influenza, sinusitis, and arthralgia
- Adverse events reported less frequently but still more often than in placebo included benign prostatic hyperplasia and atrial fibrillation

This summary does not reflect the full safety profile - see https://pi.esperion.com/nexlizet/nexlizet-pi.pdf